Quick Answer
LENZ Therapeutics, Inc. reported Research And Development Expense of $18.67 million for the year ending 2025.
- LENZ Therapeutics, Inc. showed a decrease of -37.4% in Research And Development Expense from 2024 to 2025.
- This data is from LENZ Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $423.0 thousand | Q3 2020: $2.31 million | Q1 2021: $5.38 million | Q2 2021: $12.67 million | Q3 2021: $8.68 million | Q1 2022: $18.25 million | Q2 2022: $17.78 million | Q3 2022: $18.30 million | Q1 2023: $10.33 million | Q2 2023: $12.64 million | Q3 2023: $17.00 million | Q1 2024: $10.54 million | Q2 2024: $6.95 million | Q3 2024: $6.45 million | Q1 2025: $5.82 million | Q2 2025: $9.06 million | Q3 2025: $3.79 million.
- Over the full 6 years of available data (2020 to 2025), LENZ Therapeutics, Inc.'s Research And Development Expense has grown by 104.6%.
- Historical annual values: Fiscal year 2025: $18.67 million | Fiscal year 2024: $29.80 million | Fiscal year 2023: $59.50 million | Fiscal year 2022: $72.79 million | Fiscal year 2021: $37.93 million | Fiscal year 2020: $9.12 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: